Safety and tolerability of quinupristin/dalfopristin: Administration guidelines

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue TOPIC A, 1999, Pages 37-46

  Rubinstein, E ^a   Prokocimer, P ^b   Talbot, G H ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; BILIRUBIN; BILIRUBIN GLUCURONIDE; CYCLOSPORIN; CYTOCHROME P450; DALFOPRISTIN PLUS QUINUPRISTIN; MIDAZOLAM; NIFEDIPINE; SODIUM CHLORIDE; TERFENADINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; BILIRUBIN BLOOD LEVEL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; EDEMA; HUMAN; INFLAMMATION; INNER EAR DISEASE; META ANALYSIS; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PAIN; PHYSICAL CHEMISTRY; PRACTICE GUIDELINE; QT INTERVAL; RASH; REVIEW; THROMBOPHLEBITIS; VOMITING;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG INTERACTIONS; DRUG STABILITY; HUMANS; VIRGINIAMYCIN;

EID: 0032851549     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.suppl_1.37     Document Type: Review

References (17)

1. Dowzicky, M., Nadler, H. L., Feger, C., Talbot, G., Bompart, F. & Pease, M. (1998). Evaluation of in vitro activity of quinupristin/ dalfopristin (Q/D) and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates. American Journal of Medicine 104, 34S-42S.
2. Beal, J. for the Global Synercid SSSI Study Group. (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (cefazolin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2316, p. 44. International Society of Chemotherapy, Sydney, Australia.
3. Fagon, J. Y. for the Global Synercid NP Study Group. (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) plus aztreonam versus vancomycin plus aztreonam in the treatment of Gram-positive nosocomial pneumoniae (NP). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2315, p. 44. International Society of Chemotherapy, Sydney, Australia.
4. Nichols, R. for the U.S. Synercid SSSI Study Group. (1997). Randomized, comparative, multicenter, open study of quinupristin/ dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (oxacillin or vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2314, p. 43. International Society of Chemotherapy, Sydney, Australia.
5. Raad, I. for the Global Synercid CRGPB Study Group. (1997). Dose-ranging, randomized, multicenter, open phase II study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus vancomycin in the treatment of catheter-related, Gram-positive bacteremia (CRGPB). In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2319, p. 45. International Society of Chemotherapy, Sydney, Australia.
6. Talbot, G. H., Barriere, S., Cerwinka, S., Kreter B., Lilienthal, F., Nadler, H. et al. (1997). Efficacy of quinupristin/dalfopristin (Q.D, RP 59500, Synercid) in the treatment of patients with positive blood cultures in global phase III studies. In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2317, p. 44. International Society of Chemotherapy, Sydney, Australia.
7. Moellering, R. C. & Linden, P. K. for the Synercid Emergency-use Study Group. (1997). Efficacy and safety of quinupristin/dalfopristin (RP 59500, Synercid) in the treatment of vancomycin-resistant Enterococcus faecium (VREF) infections. In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2320, p. 45. International Society of Chemotherapy, Sydney, Australia.
8. Bompart, F., Dorr, M. B., Bekele, T., Barriere, S., Rey, J., Vesseau, C. et al. (1998). Overview of the safety and tolerability of quinupristin/dalfopristin (Synercid) in the global development program. In Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides (ICMASK), Barcelona Spain, 1998. ICMAS-KO.
9. Data on File, Rhône-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA, USA.
10. Talbot, G. H. & Zhu, G. R. (1998). Characterization of arthralgia/ myalgia associated with quinupristin/dalfopristin. In Abstracts of the Thirty-Sixth Infectious Disease Society of America Annual Meeting, Denver, CO, USA, 1998. Abstract 53, p. 84. Infectious Disease Society of America, Alexandria, VA, USA.
11. Launay, O., Chemlal, K., Andrieu, V. & Carbon, C. (1997). Severe reversible reticulocytopenic anemia associated with quinupristin/dalfopristin RPR5900 therapy. Clinical Infectious Diseases 2, 156.
12. Ballow, C., Chevalier, P., Forrest, A., Geary, W., Montay, G. & Rey, J. (1997). Randomized, crossover, phase I study of the interaction between quinupristin/dalfopristin (Q/D, RP 59500, Synercid) at steady state and cyclosporine in healthy volunteers. In Programme and Abstracts of the Twentieth International Congress of Chemotherapy (ICC), Sydney, Australia, 1997. Abstract 2312, p. 43. International Society of Chemotherapy, Sydney, Australia.
13. Stamatakis, M. K. & Richards, J. G. (1997). Interaction between quinupristin/dalfopristin and cydosporine. Annals of Pharmacotherapy 31, 576-8.
14. Linden, P. K., Talbot, G. & Bompart, F. (1998). Effect of quinupristin/dalfopristin on FK-506 (tacrolimus) blood levels in liver transplant recipients. In Fourth International Conference on the Macrolides, Azalides, Streptogramins & Ketolides (ICMASK), Barcelona, Spain, 1998. ICMAS-KO.
15. Vasselle, B., Bécart, A., Thépot, C. & Bounine, J.-P. (1998). Stability of quinupristin/dalfopristin (RP59500) solutions and compatibility studies for use in clinical conditions. Pharmacotherapy 182, 432.
16. Nachman, S., Phillips, A., Gray, S. L. & Talbot, G. H. (1998). Treatment of vancomycin-resistant Enterococcus faecium central nervous system infection with intrathecal administration of quinupristin/dalfopristin. In Abstracts of the Thirty-Eighth Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, USA, 1998. Poster No. E167, p.217. American Society for Microbiology, Washington, DC.
17. Moses, J. E., Brown, E., Lynn, W., White, J., Goldberg, L. K. & Talbot, G. H. (1998). Treatment of vancomycin-resistant Enterococcus faecium CAPD-associated peritonitis with intraperitoneal administration of quinupristin/dalfopristin. Abstracts of the Thirty-Eighth Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, USA, 1998. Abstract MN-52, p. 603. American Society for Microbiology, Washington, DC.